NIH researchers identify regulatory cells that shield against inflammatory bowel disease
Clinical Scorecard: NIH Scientists Discover Regulatory Cells That Protect Against Inflammatory Bowel Disease
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | |
| Care Setting | Clinical research. |
Key Highlights
- Discovery of intramucosal GPR15-guided regulatory CD8+ T lymphocytes (CD8+ TIGR cells).
- Defective GPR15 gene variants linked to severe inflammation in IBD patients.
- Current treatments often involve broad immune suppression with associated risks.
Guideline-Based Recommendations
Diagnosis
Management
- Therapies that restore GPR15 signaling or enhance CD8+ TIGR cell migration should be directly attributed.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with severe, early-onset IBD.
Current treatments include corticosteroids, biologics, or anti-TNF therapies, but many patients do not respond adequately.
Clinical Best Practices
- Utilize genetic testing for GPR15 mutations in IBD diagnosis.
Related Resources & Content
